Viking Therapeutics Announces Phase 1 Trial for Weight Loss Drug Targeting Amylin and Calcitonin Pathways

Viking Therapeutics (VKTX) has initiated a phase 1 trial for its weight loss drug candidate, VK3019, which targets the amylin and calcitonin pathways. This marks Viking's first obesity treatment outside of GLP-1-based therapies used by competitors like Eli Lilly (LLY) and Novo Nordisk (NVO). Preclinical data showed up to 8% weight reduction in animal models.

By Alex Carchidi · Motley Fool · July 18, 2026, 19:45 UTC

Tickers: $LLY $NVO $VKTX

Topics: amylin hormone GLP-1 pathway obesity drugs

Read the full article at Motley Fool

More World news

EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC